Bioperfectus SARS-CoV-2 Antigen Rapid Test Kit with High Sensitivity and Specificity Assists in Fight against COVID-19 Pandemic

Despite their growing demand, there has been a shortage of COVID-19 rapid antigen tests in Europe due to the heavy reliance of EU countries on rapid antigen tests as a surplus testing option through the next phase of the pandemic, slow pace of vaccination, and a comparatively weak supply chain.

Bioperfectus Novel Corona Virus (SARS-CoV-2) Antigen Rapid Test Kit with its clinical proven accuracy is helping healthcare workers to quickly find out whether someone is currently at risk of spreading the disease, which will effectively curb the further spread of the virus. Bioperfectus COVID-19 rapid antigen test has been clinically proven to have high sensitivity of 96.7% and specificity of 97.9% by several institutes worldwide. Additionally, in a recent evaluation performed by the UK Department of Health and Social Care, Bioperfectus COVID-19 rapid antigen test showed no drop off in sensitivity when compared with the wild type with respect to the following variants - VOC1 Kent, UK, B.1.1.7 and VOC2 South Africa, B.1.351.

Bioperfectus Novel Corona Virus (SARS-CoV-2) Ag Rapid Test offers nasal, nasopharyngeal and oropharyngeal swab in both sterile tube and sterile peel-down pouch packages to meet the varied testing demands in different clinical laboratories across the world. Bioperfectus COVID-19 rapid antigen test also offers additional advantages such as fast results within 15 minutes, easy three-step use, swab with optional protective jacket to avoid biohazard, quality control for reliable results, and inclusion of all necessary components in the kit.

Related Links:
Jiangsu Bioperfectus Technologies Co., Ltd.